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Abstract
The lower detection rate of (3) (4) (5) . Magnetic resonance imaging (MRI) on the other hand, offers superior sensitivity compared to CT concerning infiltration of the primary tumor into adjacent organs and detection of metastasis to parenchymatous organs like the liver, the brain or the kidneys (6) (7) (8) . In addition, MRI provides valuable functional information from quantitative and multiparametric imaging (9) . With the introduction of fully integrated PET/MRI systems, PET and MRI can be used synergistically in a single modality taking advantage of an exact correlation between FDG-avid lesions and the anatomic details obtained by MR images (10) (11) (12) ). Yet, regarding lung imaging, even when using high spatial resolution T1-weighted (T1w) 3 dimensional (3D) gradient echo (GRE) sequences (e.g. volume-interpolated breathholdexamination (VIBE)) recommended for the identification of small pulmonary nodules (13-15), PET/MRI seems to be outmatched by PET/CT (16) . Underlying reasons are found in PET/MRI's lower sensitivity regarding 18 F-FDG-negative lesions (17, 18) owing to a low proton density in aerated lungs, fast decay of signal caused by susceptibility artifacts at airtissue boundaries, and motion artifacts caused by breathing and cardiac pulsation. Bearing in mind the increasing utilization of whole-body PET/MRI, its lower detection rate of small lung nodules potentially representing metastases should be considered in the staging of malignant tumors. Hence, the purpose of this study was to evaluate the outcome of small lung nodules detected on 18 F-FDG PET/CT but missed by 18 F-FDG PET/MRI in terms of their presumed dignity.
Materials and Methods
Patients and inclusion criteria
Patients with a known malignancy ( F-FDG PET/CT for tumor staging on the same day were retrospectively enrolled in this study. A follow-up CT or 18 F-FDG PET/CT not less than three months after the initial examination had to be available for outcome evaluation. According to these criteria, a total of 51 patients (mean age: 56.6 ± 14.0 years; 29 female, 22 male) between May 2012 and December 2014 were eligible for retrospective analysis. The study cohort comprised patients with tumor stages I (n = 7), II (n = 7), III (n = 9), and IV (n = 28). Eight out of 51 patients were suffering from a recurrent malignancy. The study was approved by the local ethics committee and all subjects signed an informed consent form.
PET/CT Imaging
Patients underwent whole-body (i.e. head to upper thighs) 18 F-FDG PET/CT on a Biograph mCT or Biograph Duo (Siemens AG, Healthcare Sector, Erlangen, Germany) 61 ± 8 minutes after intravenous injection of a mean activity of 260 ± 60 MBq 18 F-FDG, depending on their body weights. At injection time, blood glucose levels needed to be below 150 mg/dl. Twentythree patients were examined in low-dose CT technique. In 28 patients full-dose CT scans were performed. Full-dose CT scans were conducted after intravenous injection of a contrast agent (Imeron 300, Bracco Imaging Deutschland GmbH, Konstanz, Germany). In all full-dose PET/CT scans an additionally acquired, dedicated lung scan applying a sharp b 70 or b 90 kernel in deep inspiration was used for the detection of lung nodules. CT images were displayed on lung window setting and using a slice thickness of 2 mm. For dose reduction purposes, the manufacturer-supplied solutions CareKV and CareDose 4D were used for both full-and low-dose PET/CT scans (presets: 120kV; 210mAs and 120kV; 40 mAs, respectively).
PET-acquisition time using static frames varied from 2 -3.5 minutes per bed position.
Iterative reconstruction (3 iterations, 21 subsets) with a Gaussian filter of 4.0 mm was applied.
In general, the slice thickness of reconstructed PET images was 3 mm. For attenuation correction of the PET dataset, the portal venous phase of full-dose CT scans and low-dose CT data in low-dose scans were used.
PET/MR Imaging
Whole-body (i.e. head to upper thighs) 18 F-FDG PET/MRI using Flex coils (Siemens Healthcare AG, Erlangen, Germany) was performed on a 3 Tesla Biograph mMR (Siemens Healthcare AG, Erlangen, Germany). The average delay after intravenous tracer injection was 117 ± 29 minutes. For morphologic assessment of the lungs, a transverse T1w fs VIBE sequence (TR 4.08 ms, TE 1.51 ms, slice thickness 3.5 mm, FOV 400 x 300 mm, matrix size 512 x 307.2 mm, voxel size: 1.3 x 0.8 x 3.5 mm) after contrast administration (Dotarem, Guerbet GmbH, Sulzbach, Germany) was acquired. Attenuation correction was based on a coronal 3D-Dixon-VIBE sequence (TR 3.6 ms, TE1 1.23 ms, TE2 2.46 ms, slice thickness 3.12 mm, FOV 500 x 328 mm, matrix size 192 x 121 mm, voxel size: 4.1 x 2.6 x 3.1 mm). In general, PET acquisition time was 3 minutes per bed position. PET images were acquired in list mode and reconstructed using iterative algorithm ordered-subsets expectation maximization, 3 iterations and 21 subsets. A Gaussian filter of 4.0 mm was applied. In general, the slice thickness of reconstructed PET images was 3 mm.
Follow-up imaging
Chest CT (n = 32) and whole-body 18 F-FDG PET/CT (n = 19) scans were considered appropriate for follow-up imaging and categorization of dignity of the missed lung nodules. 
Image analysis
Images were evaluated on a dedicated OsiriX Workstation (Pixmeo SARL, Bernex, Switzerland). Baseline 
Standard of reference
Since histopathological correlation could not be obtained for any of the missed lung nodules, the standard of reference to determine the outcome of a missed lung nodule was based on a) change in nodule size between baseline and follow-up imaging (Chest CT or 
Statistics
IBM SPSS Statistics 22 (IBM, Armonk, NY, USA) was used for statistical analysis. All data are given in mean ± standard deviation. Descriptive analysis was used for the calculation of the patients' characteristics and for follow-up nodule-to-nodule comparison. Similar to previous reports (19) reliability between readers was performed in a descriptive way.
Results
There was 97 % agreement between both readers on all lung nodules detected by of the four patients. This patient was initially diagnosed with a T1 N0 M0 non-small cell lung cancer in the contralateral lung. As a consequence, the contralateral lung metastasis demanded restaging to M1a (20) . As distant metastases had already been diagnosed in the other three patients, no adjustment of TNM staging was necessary in these cases.
Discussion
The intention of this study was to evaluate the outcome of small lung nodules detected on According to the reference standard, the majority (78.6 %) of these missed lung nodules was rated as benign but there was a small but relevant number (21.4 %) of undetected lung nodules that were suspicious of metastases.
The detection of small lung nodules is a key clinical demand in cancer staging as potential metastatic spread can have far-reaching effects on therapy and patient survival (1, 13, 20) .
Today, whole-body 18 F-FDG PET/CT is widely available and used not only to identify lung nodules but also to discriminate malignant from benign pulmonary masses enabling a comprehensive tumor staging in a one-stop shop examination (21) (22) (23) . On the other hand, the latest transition from a mere research modality into clinical practice raised issues regarding the eligibility of both PET components could be considered equally prone to partial volume effects in our study. However, considering that a relevant proportion of nodules were ≤ 3 mm in size partial volume effects might have been a relevant factor.
From the variety of clinically used MR sequences of the thorax, T1w 3D GRE sequences like VIBE offer the highest detection rates of small pulmonary nodules and thus served as the only morphologic dataset in this study (13) (14) (15) (28) (29) (30) . Performed in a comparatively short imaging time (approximately 20 sec), they allow for an acquisition during breath-hold with accurate fusion of simultaneously acquired PET signals (31) . Further advantages encompass high spatial resolution offering high quality depiction of lung anatomy and a lower rate of artifacts compared to 2D GRE sequences (32) . However, comparative studies examining the sensitivity of MRI and CT for lung nodules < 1 cm found that MRI still lags behind CT with detection rates ranging between 80 % and 90 %, (14, 17, 30, 33) . Signal loss because of cardiac pulsation and respiration, susceptibility artifacts arising from multiple air-tissue interfaces, and low proton density in aerated lungs are known draw backs hampering the identification of small pulmonary nodules (34) . With a detection rate of approximately 70 % for lung nodules < 0.7 cm, our results seem to support these prior investigations.
Among four patients with suspected lung metastases that were missed by 18 F-FDG PET/MRI two patients each were suffering from lung and breast cancer; two entities renowned for a high potential of developing lung metastases and thus further substantiating the suspicion of malignancy (35, 36) . However, as in three out of the four patients distant metastases had already been diagnosed a missed metastatic spread to the lungs should not be expected to have high therapeutic significance. A clinically relevant upstaging from tumor stage I to IV was required in only one of the patients. For all other patients with lung nodules missed by Although the mean follow-up interval was eleven months many patients had follow-up intervals of less than six months. In slowly growing lesions one might argue that it was difficult to exclude false negative readings. Lacking a histopathological reference standard these limitations have to be kept in mind when interpreting the results of this study.
Conclusion
Due to its lower sensitivity in detecting PET-negative lung nodules, whole-body 18 
F-FDG
PET/MRI using a T1w VIBE sequence misses a relevant proportion of small lung nodules in oncologic patients. Although the majority of missed lung nodules proved to be benign there is a considerable number of metastases among those missed nodules. However, in patients with very advanced tumor stages the clinical impact remains controversial as potential upstaging is usually more relevant in lower tumor stages.
Disclosure
No financial support was provided for this work. There were no conflicts of interest. Outcome of lung nodules according to the standard of reference (B). Tables   TABLE 1. Tumor entities within the study cohort sorted by frequency.
Tumor n
Lung cancer 12
Breast cancer 8
Ovarian cancer 7
Lymphoma 5
Gastrointestinal cancer 3
Malignant melanoma 3
Malignant mesothelioma 3
Other (< 3 cases/entity) 10 
